Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 4Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Other 2Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Deglutition Disorders 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Fibroblast Growth Factor 7 × Thoracic × Clear all
NCT00094861 2017-03-14

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Swedish Orphan Biovitrum

Phase 2 Completed
100 enrolled 19 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Deglutition Disorders, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡